Cocco, Emiliano
Schram, Alison M.
Kulick, Amanda
Misale, Sandra
Won, Helen H.
Yaeger, Rona
Razavi, Pedram
Ptashkin, Ryan
Hechtman, Jaclyn F.
Toska, Eneda
Cownie, James
Somwar, Romel
Shifman, Sophie
Mattar, Marissa
Selçuklu, S. Duygu
Samoila, Aliaksandra
Guzman, Sean
Tuch, Brian B.
Ebata, Kevin http://orcid.org/0000-0001-7166-7513
de Stanchina, Elisa
Nagy, Rebecca J.
Lanman, Richard B. http://orcid.org/0000-0001-8122-4329
Houck-Loomis, Brian
Patel, Juber A.
Berger, Michael F.
Ladanyi, Marc
Hyman, David M. http://orcid.org/0000-0001-8150-9762
Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Scaltriti, Maurizio http://orcid.org/0000-0002-5522-1447
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748, R01CA226864)
LOXO Oncology Cycle for Survival MSK Society
Article History
Received: 17 January 2019
Accepted: 2 July 2019
First Online: 12 August 2019
Competing interests
: M.S. is on the Advisory Board of the Bioscience Institute and Menarini Ricerche, has received research funds from Puma Biotechnology, Daiichi-Sankio, Targimmune, Immunomedics, and Menarini Ricerche, is a co-founder of Medendi Medical Travel, and in the past 2 years has received honoraria from Menarini Ricerche and ADC Pharma. A.D. has honoraria from Medscape, OncLive, PeerVoice, Physician Education Resources, Tyra Biosciences, Targeted Oncology, MORE Health, Research to Practice, Foundation Medicine, PeerView, AstraZeneca, Genentech/Roche, Bayer, and has consulting roles at Ignyta, Loxo Oncology, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech/Roche, Takeda, Helsinn Therapeutics, BeiGene, Hengrui Therapeutics, Exelixis, and Bayer. D.M.H. reports personal fees from Atara Biotherapeutics, Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, and AstraZeneca and research funding from Puma Biotechnology, AstraZeneca, and Loxo Oncology. R.Y. has received research support from GlaxoSmithKline, Novartis and Array and consulting fees from GlaxoSmithKline. J.F.H. has received honoraria from Medscape, the European Society of Medical Oncology, and Axiom Biotechnologies, as well as research funding from Bayer. R.S. has received research funding from Helsinn Therapeutics. M.F.B. has received honoraria for advisory board participation from Roche and research support from Illumina. M.L. has received honoraria for ad hoc advisory board participation from AstraZeneca, Bristol-Myers Squibb, Takeda, and Bayer, and research support from LOXO Oncology (for expanded Archer targeted RNAseq testing) and Helsinn Therapeutics. P.R. has received consulting fees from Novartis.